ESMO 2026 Highlights

Madrid, October 23–27, 2026

The Complete ESMO2026 Newsletter

Subscribers read it first. Subscribe to get it.

Email address

Your role

Your country

How we use your details

Free. Easy to leave.

Top 10 trials to watch

The trials the faculty picked to watch at ESMO 2026, one list per tumor group. Each trial opens its own page.

All Top 10s

Breast
10 trials
1. Abstract LBA50PANKU-BREAST01
2. Abstract 1842OFOURLIGHT-1
3. Abstract LBA25NATALEE
4. Abstract LBA27APEX-BREAST01
5. Abstract LBA51KEYNOTE-B49
6. Abstract LBA13HORIZON-BREAST06
7. Abstract LBA26POP-DURVA
8. Abstract 4ROSWITCH
9. Abstract 1ROpostMONARCH
10. Abstract LBA49DESTINY-Breast09
Lung and thoracic
10 trials
1. Abstract LBA3DeLLphi-305
2. Abstract LBA5KRASCENDO
3. Abstract LBA6SAFFRON
4. Abstract LBA67OptiTROP-Lung04
5. Abstract LBA66OptiTROP-Lung06
6. Abstract 2614OPERSEE
7. Abstract LBA69SANOVO
8. Abstract 2618ROIFCT-2103 DIAL
9. Abstract LBA71PANKU-Lung01
10. Abstract 2613OSARON
Genitourinary
10 trials
1. Abstract LBA2VOLGA
2. Abstract LBA4DASL-HiCaP
3. Abstract 3586OLITESPARK-012
4. Abstract 3587OLITESPARK-011
5. Abstract LBA56CAPItello-281
6. Abstract 3592OAK112
7. Abstract LBA53PROTEUS
8. Abstract LBA88PE-PE
9. Abstract 4734OKEYNOTE-B15
10. Abstract 3591OSWOG S2200
Gastrointestinal
10 trials
1. Abstract LBA87AZUR-1
2. Abstract LBA32CheckMate 8HW
3. Abstract 789ROTRIDENTE
4. Abstract LBA79HERIZON-GEA-01
5. Abstract 2875OKEYNOTE-975
6. Abstract 2877ROGERCOR-GONO DEWI
7. Abstract LBA77G-HOPE-001
8. Abstract LBA8HARMONi-GI1
9. Abstract LBA21ACTICCA-1
10. Abstract LBA22OPTIMUM

4Sight

The key ESMO 2026 abstracts, each a set of slides. Tap one to read it with its brief.

All ESMO 2026 4Sights

CLARITY-Gastric 01
Gastrointestinal
SAFFRON
Lung and thoracic
Krascendo 1
Lung and thoracic
DASL-HiCaP (ANZUP1801)
Genitourinary
DeLLphi-305
Lung and thoracic
VOLGA
Genitourinary
LBA1
Melanoma and skin
FLAURA2
Lung and thoracic
459O
Gastrointestinal
4736O
Genitourinary
4449RO
Breast
PEARLS/KEYNOTE-091
Lung and thoracic
RAMIRIS
Gastrointestinal
KEYNOTE-564
Genitourinary
evERA
Breast
DeLLphi-304
Lung and thoracic
LEAP-012
Gastrointestinal
PEACE-1
Genitourinary
BRIDGET
Breast
SARON
Lung and thoracic
DEWI
Gastrointestinal
KEYNOTE-866
Genitourinary
FOURLIGHT-1
Breast
PERSEE
Lung and thoracic
LITESPARK-012
Genitourinary
postMONARCH
Breast
GIM3 FATA
Breast
KEYNOTE-975
Gastrointestinal

Podium2Screen

Podium2Screen videos from ESMO 2026, newest first.

The series

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26
Genitourinary. Dr. Daniel Heng. Trial update.
Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026
Genitourinary. Dr. Andrea Necchi. Trial update.
evERA : Giredestrant + Everolimus: evERA Biomarker Analyses | Sara Tolaney | ESMO 2026
Breast. Dr. Sara Tolaney. Trial update.
VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
Genitourinary. Dr. Tom Powles. Trial update.
NEW for ESMO26: Podium2Screen Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center
Lung and thoracic. Trial update.

On The Go

Short upright videos. Tap one to watch, then swipe for the next.